Liproxstatin-1_950455-15-9_DataSheet_MedChemExpress
liproxstatin-1结构
liproxstatin-1结构Liproxstatin-1是一种小分子抑制剂，它的结构如下：Liproxstatin-1的分子式为C30H24N2O10S，分子量为608.6克/摩尔。
它是一种灰黄色的固体，其溶解度较低，但可以在有机溶剂中稳定溶解。
Liproxstatin-1的结构中包含了一个核苷酸，一个酮醛，和一个酰胺。
它的核苷酸部分包括一个含有一条碳链的六元环，以及一个含有一个氧原子的五元环。
在这两个环之间，有一个含有一对氮原子和一个含有硫原子的五元环。
这个核苷酸环上还连接着一个酮醛基团和一个酰胺基团。
酮醛基团与核苷酸环的一个碳原子相连，并包括一个含有两个氢原子的三元环。
而酰胺基团与酮醛基团相连，并包括一个含有一个氧原子的四元环。
Liproxstatin-1的分子结构使其具有抗氧化和抗炎症的作用。
它可以通过抑制一氧化氮合酶和过氧化氢酶的活性，减少活性氧的产生，从而防止氧化应激的发生。
此外，Liproxstatin-1还可以减少炎症反应中介物的产生，抑制炎症细胞的活化，从而降低炎症反应的强度和持续时间。
Liproxstatin-1的抗氧化和抗炎症作用使其在多种疾病的治疗中具有潜力。
研究已经表明，Liproxstatin-1可以通过减少氧化应激和炎症反应来抑制肿瘤的生长和转移。
此外，Liproxstatin-1还可以保护心脏、肝脏和肾脏等器官免受氧化应激和炎症的损伤。
值得注意的是，Liproxstatin-1具有一定的毒性。
一些研究结果显示，Liproxstatin-1可以对正常细胞产生负面影响。
因此，在使用Liproxstatin-1作为药物时，需要仔细评估其安全性和有效性，并在合适的剂量和适当的治疗期限内使用。
总之，Liproxstatin-1是一种具有抗氧化和抗炎症作用的小分子抑制剂。
它的分子结构使其具有广泛的应用潜力，但同时也要注意其毒性和安全性的问题。
随着对Liproxstatin-1机制和作用的深入研究，相信它将在多种疾病的治疗中发挥重要的作用。
CelLyticTM系列蛋白裂解液
高效率 操作步骤简单,省时 高得率 得率远优于传统冻融或超声法 高活性 温和非变性条件下抽提活性蛋白 高兼容 与蛋白酶抑制剂、鳌合剂、离液剂等很好兼容 抽提的蛋白无需去除CelLyticTM 试剂即可进行下游实验： 亲和纯化 Western blot 凝胶迁移检测 报告基因检测……
566.28 2136.42 566.28 3758.04 2535.39 3938.22
501.93 3320.46
566.28 2084.94 3989.7
527.67 3629.34 5302.44
促销价¥
384.81 2375.80 685.97 2375.80 409.91 1505.79 2651.86 1054.05 1648.00 393.18 1187.90 217.50 711.07 4341.69 368.08 1271.56
哺乳动物细胞和组织裂解
C2978
CelLytic™ M Cell Lysis Reagent
C3228
CelLytic™ MT Cell Lysis Reagent
CE0500 NXTRACT
R0278
CelLytic™ MEM Protein Extraction Kit CelLytic™ NuCLEAR™ Extraction Kit For mammalian tissue or cultured cells RIPA Buffer
P8215
Protease Inhibitor Cocktail for use with fungal and yeast extracts
P8465
Protease Inhibitor Cocktail for use with bacterial cell extracts
hss-p-5.75.09 - hyaluronic acid derivatives说明书
5.75.09Section:Prescription DrugsEffective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject:Hyaluronic Acid DerivativesPage:1 of 7Last Review Date:March 13, 2020Hyaluronic Acid DerivativesDescriptionDurolane, Euflexxa, GelSyn-3, GenVisc 850, Hyalgan , SodiumHyaluronate, Supartz , Synojoynt*, Triluron, TriVisc, Visco-3 (sodium hyaluronate)Gel-ONE , Hymovis, Monovisc, Orthovisc (hyaluronan)Synvisc, Synvisc-One (hylan G-F 20)Bolded medications are the preferred products*These medications are included in this policy but are not available in the market as of yetBackgroundOsteoarthritis of the knee is a disease in which the elastoviscous property of the synovial fluid in the knee joint becomes diminished, resulting in less protection and shock absorption. Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Sodium Hyaluronate, Synvisc, Synvisc-One, Supartz, Synojoynt, Triluron, TriVisc, Visco-3 are hyaluronan derivatives that are injected into the knee joints to increase the elastoviscous properties of arthritic joint fluid and slow its outflow from the joint . The goal of therapy is torestore the viscoelasticity in the affected joints, thereby decreasing pain, improving mobility, and restoring the natural protective functions (1).The American College of Rheumatology (ACR) updated its guidelines for the treatment of osteoarthritis (OA) of the knee in 2012. In mild symptomatic OA, treatment may be limited toFederal Employee Program® 1310 G Street, N.W.Washington, D.C. 20005 202.942.1000Fax 202.942.1125Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 2 of 7patient education, physical and occupational therapy and other non-pharmacologic modalities. Nonpharmacologic modalities strongly recommended for the management of knee OA were aerobic, aquatic, and/or resistance exercises as well as weight loss for overweight patients. Nonpharmacologic modalities conditionally recommended for knee OA included medial wedge insoles for valgus knee OA, subtalar strapped lateral insoles for varus knee OA, medially directed patellar taping, manual therapy, walking aids, thermal agents, tai chi, self-management programs, and psychosocial interventions. Pharmacologic modalities conditionally recommended for the initial management of patients with knee OA included acetaminophen, oral and topical NSAIDs, tramadol, and intraarticular corticosteroid injections (1).Regulatory StatusFDA-approved indication: Hyaluronic acid derivatives are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy, simple analgesics (e.g., acetaminophen), NSAIDs, tramadol, or intra-articular steroid injections (2-18).The hyaluronic acid derivatives are contraindicated for use in patients with known hypersensitivity to hyaluronan (sodium hyaluronate) preparations. Orthovisc lists hypersensitivity to gram positive bacterial proteins as an additional contraindication (4). Caution should be exercised when Gel-One, Hyalgan, Visco-3, Synvisc, Synvisc-One, Supartz, and Triluron are administered to patients with allergies to avian proteins, feathers, and egg products (3-8, 18).Hyaluronic acid derivatives are contraindicated to treat patients with knee joint infections, infections or skin diseases in the area of the injection site (2-17).A treatment cycle for most of the hyaluronan derivatives typically involves multiple weekly injections. Euflexxa, GelSyn-3, Sodium Hyaluronate, Synvisc, Triluron, TriVisc, and Visco-3 are given for a total of three injections. Orthovisc is given for three or four injections. GenVisc 850, Supartz and Hyalgan are given for a total of three or five injections. Durolane, Gel-One, Synojoynt, and Synvisc-One differ from the other hyaluronan derivatives in that it only requires one injection. Repeat courses of hyaluronan derivatives may be administered if symptoms return (2-18).Upon the basis of high quality supporting evidence, the American Academy of Orthopedic Surgeons cannot recommend using hyaluronic acid for patients with symptomatic osteoarthritis of the knee (19).Related policiesSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 3 of 7Hyaluronate PowderPolicyThis policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.Hyaluronic acid derivatives may be considered medically necessary for the treatment of osteoarthritis of the knee and if the conditions indicated below are met.Hyaluronic acid derivatives may be considered investigational for all other indications.Prior-Approval RequirementsAge18 years or older (22 or older for Synvisc, Synvisc-One, and TriVisc)DiagnosisPatient must have the following:Osteoarthritis of the kneeAND ALL of the following:1. Inadequate response to TWO or more of the following conservative non-pharmacologic therapy:a. Cardiovascular (aerobic) activity, such as: walking, biking, stationarybike, aquatic exerciseb. Resistance exercisec. Weight reduction (for persons who are overweight)d. Participation in self-management programse. Wear of medially directed patellar tapingf. Wear of wedged insolesg. Thermal agentsh. Walking aidsi. Physical therapyj. Occupational therapy2. Inadequate response, intolerance, or contraindication to TWO or more of thefollowing:Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 4 of 7a. Acetaminophenb. Oral NSAIDsc. Topical NSAIDs3. Inadequate response, intolerance, or contraindication to intra-articularsteroid injections in which efficacy lasted less than 8 weeks4. Radiologic confirmation of Kellgren-Lawrence Scale score of grade 2 orgreater5. NO dual therapy with another hyaluronic acid injectable6. Non-preferred medications only: Patient MUST have tried at least TWO ofthe preferred products unless the patient has a valid medical exception (e.g.inadequate treatment response, intolerance, contraindication)Prior – Approval Renewal RequirementsAge18 years or older (22 or older for Synvisc, Synvisc-One, and TriVisc)DiagnosisPatient must have the following:Osteoarthritis of the kneeAND ALL of the following:1. Documentation of improvement in pain with previous course of treatment2. At least 12 months has elapsed since last injection of the prior treatmentcycle3. Documentation of reduction of dosing of NSAIDs or other analgesicsduring the 12 month period following the last injection of the prior treatmentcycle4. NO dual therapy with another hyaluronic acid injectable5. Non-preferred medications only: Patient MUST have tried at least TWOof the preferred products unless the patient has a valid medical exception(e.g. inadequate treatment response, intolerance, contraindication) Policy GuidelinesPre - PA AllowanceNoneSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 5 of 7Prior - Approval LimitsDuration12 monthsQuantity One course of therapy for each kneePrior – Approval Renewal LimitsSame as aboveRationaleSummaryOsteoarthritis of the knee is a disease in which the elastoviscous property of the synovial fluid in the knee joint becomes diminished, resulting in less protection and shock absorption. Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Sodium Hyaluronate, Synvisc, Synvisc-One, Supartz, Synojoynt, Triluron, TriVisc, Visco-3 are hyaluronan derivatives that are injected into the knee joints to increase the elastoviscous properties of arthritic joint fluid and slow its outflow from the joint. The goal of therapy is to restore the viscoelasticity in the affected joints, thereby decreasing pain, improving mobility, and restoring the natural protective functions (1-18).Prior approval is required to ensure the safe, clinically appropriate and cost effective use of the hyaluronic acid derivatives while maintaining optimal therapeutic outcomes.References1. American College of Rheumatology, Subcommittee on Osteoarthritis Guidelines.Recommendations for the medical management of osteoarthritis of the hip and knee:2012 update. Arthritis Care & Research 2012; 64(4):465-474.2. Euflexxa [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; July 2016.3. Hyalgan [package insert]. Parsippany, NJ: Fidia Pharma USA Inc.; May 2014.4. Orthovisc [package insert]. Woburn, MA: Anika Therapeutics; June 2005.5. Supartz [package insert]. Durham, NC: Bioventus LLC; April 2015.6. Synvisc [package insert]. Ridgefield, NJ: Genzyme Corp.; December 2014.7. Synvisc-One [package insert]. Ridgefield, NJ: Genzyme Corp.; September 2014;8. Gel-One [package insert]. Warsaw, IN: Zimmer Inc.; May 2011.9. Monovisc [package insert]. Bedford, MA: Anika Therapeutics; December 2013.10. Hymovis [package insert]. Parsippany, NJ: O Fidia Pharma USA Inc.; October 2015.Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 6 of 711. GenVisc 850 [package insert]. Doylestown, PA: OrthogenRx Inc.; January 2015.12. GelSyn-3 [package insert]. Durham, NC: Bioventus LLC; January 2016.13. Durolane [package insert]. Durham, NC: Bioventus LLC; November 2017.14. Visco-3 [package insert]. Warsaw, IN: Zimmer, Inc.; May 2017.15. Sodium Hyaluronate [package insert]. North Wales, PA: Teva Pharmaceuticals USA,Inc.; March 2019.16. Synojoynt [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.;September 2019.17. TriVisc [package insert]. Doylestown, PA: OrthogenRx, Inc.; September 2018.18. Triluron [package insert]. Florham Park, NJ: Fidia Pharma USA Inc.; March 2019.19. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee.Evidence-based guideline 2nd edition. May 2013.Policy HistoryDate Action ReasonJanuary 2012 Added minimum age - only approved for adultsDecember 2012 Annual editorial review and reference updateDecember 2013 Annual editorial review and reference updateMarch 2014 Annual editorial reviewAddition of examples of non-pharmacological agents and agents of priorfailure medications.April 2014 Line-Addition of Monovisc to PAMarch 2015 Annual criteria review and reference updateMarch 2016 Change from one tried and failed to two tried and failed non-pharmacologic and pharmacologic therapies and addition of the tried and failed of intra-articular steroid and radiologic confirmation of Kellgren-Lawrence Scalescore of grade 2 or greaterAddition of HymovisPolicy # change from 5.11.04 to 5.75.09May 2016 Addition of GelSyn-3 and GenVisc 850December 2016 Annual editorial review and reference updateAdded: no dual therapy with another hyaluronic acid injectableMarch 2017 Bolded preferred products in the title pageJuly 2017 GelSyn-3 has been changed to preferredSeptember 2017 Annual reviewDecember 2017 Addition of Durolane and Visco-3March 2018 Annual editorial reviewRemoval of Tramadol from the T/F listSeptember 2019 Annual review and reference update. Addition of Sodium Hyaluronate,Synojoynt, and TriViscSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 7 of 7December 2019 Annual review. Addition of requirement to trial preferred products January 2020 Addition of TriluronMarch 2020 Annual reviewKeywordsThis policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 13, 2020 and is effective on April 1, 2020.。
Roche_Xtreme GeneHP_protocal
0910.06479774001ቢ
The recommended starting concentration is a 3:1. For most cell types, these X-tremeGENE HP DNA Transfection Reagent to DNA ratios provide excellent transfection efficiency. Further optimization may increase transfection efficiency in your particular application. In addition to varying the ratio, other parameters may also be evaluated, such as the amount of transfection complex added. For additional optimization guidelines, see Section 3, Troubleshooting and visit . Plasmid DNA • For best results, accurately determine the plasmid DNA concentration using 260-nm absorption; estimates of DNA by measuring gel band density are not recommended. Determine DNA purity using a 260 nm/280 nm ratio (the optimal ratio is 1.8). • Prepare the plasmid DNA solution using sterile TE (Tris/EDTA) buffer or sterile water at a concentration of 0.1 to 2.0 µg/µl. • Use high quality DNA preparation kits to obtain endotoxin-free DNA. Cell Culture Conditions • Minimize intra- and inter-experimental variance in transfection efficiency using cells that are regularly passaged, proliferating well in a log-growth phase, and plated at a consistent density. • For best results, accurately quantify cell concentration using a hematocytometer or automated system. • Cells must be healthy and free of Mycoplasma. • Cells should have a low passage number to achieve best results. Other Media Additives In some cell types, antimicrobial agents (e.g., antibiotics and fungicides) commonly included in cell-culture media may adversely affect the transfection efficiency of X-tremeGENE HP DNA Transfection Reagent. If possible, exclude additives in initial experiments. Once high-efficiency conditions have been established, these components can be added back while monitoring transfection results. Cell growth and/or transfection efficiency may be affected by variations in serum quality and medium formulations. Verification of Vector Function Optimize transfection conditions using a known positive-control reporter gene construct before transfecting cells with a new vector construct: • Determine transfection efficiency using a reporter gene assay, such as -Gal*, Luciferase*, or SEAP*. • Sequence flanking vector insert regions to verify the integrity of your new construct. 2.2 Transfection Procedure Adherent Cells: Plate cells approximately 24 hours before transfection making sure cells are at the optimal concentration in the appropriate cell culture vessel. Suspension Cells: Plate freshly passaged cells at optimal concentration.
liproxstatin-1结构
liproxstatin-1结构Liproxstatin-1是一种新型的药物，具有潜力治疗多种疾病，包括神经退行性疾病，心血管疾病和肿瘤等。
它是一种蛋白质复合物，其中包括白介素-6诱导亚基共同激活蛋白（STAT3）的抑制剂和蛋白酶体蛋白酶α的抑制剂。
Liproxstatin-1是通过通过选择性抑制STAT3和蛋白体蛋白水平来产生其药效的。
这种化合物主要用于治疗由炎症引起的疾病，特别是自身免疫疾病和癌症等疾病。
其作用机制是通过抑制NF-κB和STAT3信号通路的激活来抑制炎症。
此外，它还可以对多种细胞因子进行抑制，例如IL-6等。
Liproxstatin-1最初是由日本的一家制药公司发现的，目前已经被引起了学术界和产业界的广泛关注。
其分子结构为C20H17NO4，呈深棕色粉末，可溶于DMSO和乙醇中，而在水中的溶解度较低。
从药理学的角度来看，Liproxstatin-1的特殊结构和药效的产生有着密切的关系。
在分子结构中，Liproxstatin-1包含了一个苯环和一个五元杂环，而杂环内部还有一个双键和一个亚胺基团。
在苯环中，有两个取代基，其中一个是碘原子，另一个是甲氧基团。
这种分子结构使其能够与蛋白质和其他生物大分子结合，并对其产生影响。
此外，由于Liproxstatin-1本身具有强抗氧化能力，能够清除自由基，从而减少氧化应激对细胞的影响。
这些特性使其在治疗神经退行性疾病和心血管疾病等方面具有潜在的作用。
总之，Liproxstatin-1作为一种新型的药物，具有潜力治疗多种疾病，其分子结构和药效的产生密切相关。
对于该化合物的进一步研究和开发将有望为人类健康和医疗事业做出重大贡献。
QPCR及QRT-PCR系列产品
Invitrogen的ICFC系列产品促销1．QPCR及QRT-PCR系列产品Invitrogen公司专门为中国客户提供的定量PCR试剂盒，结合了 UDG 防止残余污染技术和SYBR® Green I 荧光染料（存在于SYBR® Green I荧光定量PCR试剂盒中），在美国接受了严格的质量监控，可提供极高灵敏度的目的序列定量检测，线性剂量低，反应浓度范围很大。
qPCR Supermix-- 即用型反应剂，专为高特异性、实时定量DNA扩增设计UDG-- 防止携带污染物，减少克隆片段假阳性结果ROX参考染料-- 适用ABI仪器的校正染料产品信息活动时间：即日起至2009年4月30日2．Gibco南美胎牛血清即日起凡优惠价¥1780购买Gibco胎牛血清500ml（目录号:C2027050）即可获赠送价值¥250现金抵用券。
您可以凭现金抵用券在英韦创津公司购买任何商品，此券有效期至2009年5月31日。
产品信息活动时间：即日起至2009年4月30日独特的采集方式：GIBCO采用无菌心脏穿刺的方式采血原装直送，避免污染：原产地采集、加工、检测、包装。
完善的质控：采集、处理、检测、运输等环节都有文件和证书。
3．Invitrogen TA Cloning克隆产品专门用于克隆Taq聚合酶扩增的PCR产物。
采用pCR载体，能产生80%以上的重组产物，90%以上重组产物都包含插入片段。
产品信息活动时间：即日起至2009年5月31日附：pCR载体优点及图谱：3’-T突出端可直接连接Taq扩增的PCR产物可选择T7或T7和Sp6启动子进行体外RNA转录和测序侧向EcoRⅠ位点的通用多接头位点方便了插入片段的切离可以选择卡那霉素或氨苄青霉素进行筛选非常简便的蓝/白克隆筛选具有M13正向和反向引物位点，方便测序4．GIBCO液体培养基系列产品创立近50年的历史，品质优秀，产品种类丰富；为了中国用户利益，特建立国内生产线；所有产品，从原材料到生产全部按照GIBCO质量标准进行，每批均送抵美国公司总部质检合格后，才在国内销售。
自-罗氏proGRP产品说明书
【产品名称】通用名称:胃泌素释放肽前体检测试剂盒(电化学发光法)英文名称:ProGRＰ【包装规格】100测试/盒【预期用途】主要用途用于体外定量检测人血浆和血清中的胃泌素释放肽前体(ＰｒoGRＰ)。
该分析结合其他临床方法可辅助用于肺癌的鉴别诊断和小细胞肺癌患者的管理。
结果必须根据标准临床诊疗指南结合其他方法进行解释。
Elecsys和cobas e免疫分析仪的工作原理是电化学发光免疫分析“ＥCLIＡ”。
临床应用胃泌素释放肽（GRP）是一种重要的调节分子,和人体许多生理功能、病理状态有关。
它是一种胃肠激素,是哺乳动物同源的两栖动物蛙皮素,最初从猪胃粘膜中分离,广泛分布于哺乳动物的神经系统、胃肠道和呼吸道。
1随着信号肽解离,它的148个氨基酸的前蛋白原进一步分解生成2７个氨基酸的胃泌素释放肽和68个氨基酸的胃泌素释放肽前体(PrｏGRP)。
由于胃泌素释放肽的半衰期很短,只有2分钟，不可能在血中检测到。
因此研发出一种检测胃泌素释放肽前体（３1-98)的测定法，一个羧基端区域,常见于三种类型的人胃泌素释放肽前体剪接变体。
现已证明血清胃泌素释放肽前体(３1-9８)可作为小细胞肺癌(SCLC)病人的可靠标志物。
２,3，４,5Eleｃsys胃泌素释放肽前体检测血浆和血清中的胃泌素释放肽前体（31-98）。
胃泌素释放肽前体和神经特异性烯醇化酶(NＳE）是与神经内分泌源组织和肿瘤有关的两种分子。
胃泌素释放肽前体水平升高见于多种神经内分泌源肿瘤，包括小细胞肺癌、类癌、具有神经内分泌功能的未分化大细胞肺癌、甲状腺髓样癌6、其他神经内分泌恶性肿瘤6以及具有神经内分泌功能的不依赖雄激素的前列腺癌亚组。
7良性疾病中的胃泌素释放肽前体：文献报道胃泌素释放肽前体血清浓度在2-５0pg/mＬ时为正常。
8但是，在一项对包括肝脏疾病在内的良性疾病（肾功能不全除外）病人的研究中，有2.５％的病人胃泌素释放肽前体血清水平＞5０pｇ/mL。
蛋白酶抑制剂混合液(100×PIC)
产品组成：
名称
编号
蛋白酶抑制剂混合液(100×PIC)
使用说明书
PI0015 1ml
PI0015
Storage
5×1mlቤተ መጻሕፍቲ ባይዱ1份
-20℃ 避光
操作步骤（仅供参考）：
1、 开盖前，请低速离心一下，以便将黏附于管壁的液体甩至管底。 2、 使用时, 根据裂解液的用量加入 1%的蛋白酶抑制剂混合液(100×PIC)，使其终浓度达
北京雷根生物技术有限公司
蛋白酶抑制剂混合液(100×PIC)
产品简介：
蛋白酶抑制剂(Protease Inhibitor)指与蛋白酶分子活性中心上的一些基团结合，使蛋 白酶活力下降，甚至消失，但不使酶蛋白变性的物质。蛋白酶抑制剂有很多种，包括 EDTA、 E-64、NaVO3、Bestatin、Leupetin、Pepstatin A、Aprotinin 等，可以有效抑制蛋白的 降解，并维持原有的蛋白间相互作用。
到 1×。
注意事项：
1、 蛋白酶抑制剂混合液有轻微刺激性，小心操作，同时应避免反复冻融。 2、 为了您的安全和健康，请穿实验服并戴一次性手套操作。
有效期：12 个月有效。
相关产品：
产品编号 PI0011 PS0013 PT0001
产品名称 苯甲基磺酰氟溶液(PMSF,100mmol/L) RIPA 裂解液(强) BCA 法蛋白定量试剂盒
Leagene 蛋 白 酶 抑 制 剂 混 合 液 (100 × PIC) 主 要 由 Leupetin 、 Pepstatin A 、 Aprotinin、E-64 等组成，不含 EDTA。该混合物可以抑制绝大多数蛋白酶活性，包括丝氨 酸蛋白酶、半胱胺酸蛋白酶、胃蛋白酶、胰蛋白酶、木瓜蛋白酶等。该蛋白酶抑制剂混合 液是 100×的浓缩的 DMSO 溶液，适用于从哺乳动物组织、细胞中提取蛋白质，能够更有 效的获得目的蛋白质。提取出来的蛋白可以用于 Western Blot、免疫共沉淀等试验。